MaxCyte, Inc.
- MXCT
- NASDAQ
- Biotechnology
- Cell Electroporation Systems
- Cell Therapy Tools
$1.30
Quote Oct 16, 2026, 08:00 PM UTC
+8.33%over the last month
Max drawdown −22.2%From 1-month high 0.0%3 months +11.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$134.2M
Quote Oct 16
Next earnings
Nov 10
Expected, not confirmed
Analyst target
$6.00
+361.5% from here
Floor
$1.25
3.5% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MXCTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $7.3M
- Product$4.1M56.4%
- License$2.6M35.6%
- Other / not reported$583,0008.0%
Industry
Biotechnology
Employees
91
Founded
1998